Cancer Immunology Research · 2013 · 167 citations · 20 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentCancer ImmunotherapyMacrophage BiologyTumor Immune MicroenvironmentTumor ImmunopathologyTumor Microenvironment ModulationTumor-associated MacrophagesCancer-associated Fibroblast-mediated Immune SuppressionCancer-associated ImmunosuppressionCancer-associated MacrophagesDiphtheria ToxinFibroblast ActivationHost Immune SuppressionImmune Suppression MechanismsImmunosuppressive Function
The depletion of tumor stromal cells that are marked by their expression of the membrane protein fibroblast activation protein-α (FAP) overcomes immune suppression and allows an anticancer cell immune response to control tumor growth. In subcutaneous tumors established with immunogenic Lewis lung carcinoma cells expressing ovalbumin (LL2/OVA), the FAP(+) population is comprised of CD45(+) and CD45(-) cells. In the present study, we further characterize the tumoral FAP(+)/CD45(+) population as a minor subpopulation of F4/80(hi)/CCR2(+)/CD206(+) M2 macrophages. Using bone marrow chimeric mice in which the primate diphtheria toxin receptor is restricted either to the FAP(+)/CD45(+) or to the FAP(+)/CD45(-) subset, we demonstrate by conditionally depleting each subset that both independently contribute to the immune-suppressive tumor microenvironment. A basis for the function of the FAP(+)/CD45(+) subset is shown to be the immune inhibitory enzyme, heme oxygenase-1 (HO-1). The FAP(+)/CD45(+) cells are the major tumoral source of HO-1, and an inhibitor of HO-1, Sn mesoporphyrin, causes the same extent of immune-dependent arrest of LL2/OVA tumor growth as does the depletion of these cells. Because this observation of immune suppression by HO-1 expressed by the FAP(+)/CD45(+) stromal cell is replicated in a transplanted model of pancreatic ductal adenocarcinoma, we conclude that pharmacologically targeting this enzyme may improve cancer immunotherapy.
20
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Hirokazu Matsushita, Matthew D. Vesely, Daniel C. Koboldt et al. · Nature · 2012 · 1.3K citations · Full text
Medicine, Cancer Biology, Oncology +16
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Matthew Kraman, Paul Bambrough, James N. Arnold et al. · Science · 2010 · 1.1K citations
Medicine, Immunology, Oncology +17